clinical trial · NCT06502977
Study Evaluating Tarlatamab in Chinese Participants With Advanced Small Cell Lung Cancer After Two or More Prior Lines of Treatment
Amgen·phase2·active not recruiting·n = 32
Extensive Stage Small Cell Lung CancerTarlatamab
brief summary
The primary aim of this study is to evaluate the efficacy of tarlatamab as assessed by objective response rate (ORR) based on blinded independent central review (BICR) per Response Evaluation Criteria in Solid Tumors version 1.1 (RECIST 1.1).
started
Aug 27, 2024
primary completion
Mar 28, 2025
completion
Jan 8, 2027
last updated
Apr 15, 2026
official title
Phase 2a Study Evaluating the Efficacy, Safety, Tolerability and Pharmacokinetics of Tarlatamab in Chinese Subjects With Advanced Small Cell Lung Cancer After Two or More Prior Lines of Treatment (DeLLphi-307)
sourced from ClinicalTrials.gov · pharmadog mirrors structured fields, not the full protocol